Aptevo Therapeutics Inc. (APVO )

Currency in USD Disclaimer
$0.23 -$0.01 (-2.74%)
Open 12/03/2024
$0.23
$0.25
$0.14
$10.8

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol APVO
  • Company Aptevo Therapeutics Inc.
  • Price $0.23
  • Changes Percentage -2.74
  • Change -0.0065
  • Day Low $0.23
  • Day High $0.25
  • Year High $10.8
  • Year Low $0.14
  • Market Cap $4,304,063
  • Price Avg 50 EMA (D) $0.23
  • Price Avg 200 EMA (D) $1.17
  • Exchange NASDAQ
  • Volume 829,585
  • Average Volume 7,029,922
  • Open $0.24
  • Previous Close $0.24
  • EPS -11.24
  • PE -0.02
  • Earnings Announcement 2025-03-04 05:00:00
  • Shares Outstanding $18,512,100

Company brief: APTEVO THERAPEUTICS INC. (APVO )

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Corporation News

Income Statement